NCT00444223

Brief Summary

RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable lung-cancer

Timeline
Completed

Started May 2004

Typical duration for not_applicable lung-cancer

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 4, 2004

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

March 5, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 7, 2007

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2008

Completed
Last Updated

August 5, 2020

Status Verified

February 1, 2016

Enrollment Period

4 years

First QC Date

March 5, 2007

Last Update Submit

August 3, 2020

Conditions

Lung Cancer

Keywords

stage IIIA non-small cell lung cancerstage IIIB non-small cell lung cancerstage IV non-small cell lung cancer

Outcome Measures

Primary Outcomes (1)

  • Biodistribution of fluorine F 18 FEQA

    1 day

Study Arms (1)

fluorine F 18 FEQA + positron emission tomography

EXPERIMENTAL
Procedure: fluorine F 18 FEQA + positron emission tomography

Interventions

fluorine F 18 FEQA + positron emission tomographyPROCEDURE
fluorine F 18 FEQA + positron emission tomography

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Must meet 1 of the following criteria:
  • Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy
  • Stage III or IV disease
  • Clinically assessed with
  • Healthy participant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles, California, 90095-1781, United States

Location

MeSH Terms

Conditions

Lung NeoplasmsCarcinoma, Non-Small-Cell Lung

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Johannes Czernin, MD

    Jonsson Comprehensive Cancer Center

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 5, 2007

First Posted

March 7, 2007

Study Start

May 4, 2004

Primary Completion

May 15, 2008

Study Completion

May 15, 2008

Last Updated

August 5, 2020

Record last verified: 2016-02

Locations

US(1)